209412-06-6Relevant articles and documents
Rapid synthesis of VX-745: p38 MAP kinase inhibition in Werner syndrome cells
Bagley, Mark C.,Davis, Terence,Dix, Matthew C.,Rokicki, Michal J.,Kipling, David
, p. 5107 - 5110 (2007)
The p38 mitogen-activated protein kinase inhibitor VX-745 is prepared rapidly and efficiently in a four-step sequence using a combination of conductive heating and microwave-mediated steps. Its inhibitory activity was confirmed in hTERT immortalized HCA2
The discovery of VX-745: A novel and selective p38α kinase inhibitor
Duffy, John P.,Harrington, Edmund M.,Salituro, Francesco G.,Cochran, John E.,Green, Jeremy,Gao, Huai,Bemis, Guy W.,Evindar, Ghotas,Galullo, Vincent P.,Ford, Pamella J.,Germann, Ursula A.,Wilson, Keith P.,Bellon, Steven F.,Chen, Guanging,Taslimi, Paul,Jones, Peter,Huang, Cassey,Pazhanisamy,Wang, Yow-Ming,Murcko, Mark A.,Su, Michael S.S.
supporting information; experimental part, p. 758 - 763 (2011/12/03)
The synthesis of novel, selective, orally active 2,5-disubstituted 6H-pyrimido[1,6-b]pyridazin-6-one p38α inhibitors is described. Application of structural information from enzyme-ligand complexes guided the selection of screening compounds, leading to t
An improved synthesis of 5-(2,6-dichlorophenyl)-2-(phenylthio)-6H- pyrimido[1,6-b]pyridazin-6-one (a VX-745 analog)
Treu, Matthias,Jordis, Ulrich,Lee, Ving J.
, p. 959 - 963 (2007/10/03)
An improved procedure for the synthesis an analog of the p38 inhibitor compound VX-745 is reported.